Allergy Therapeutics PLC Exercise of Options and Total Voting Rights (9644S)
November 09 2023 - 4:48AM
UK Regulatory
TIDMAGY
RNS Number : 9644S
Allergy Therapeutics PLC
09 November 2023
Al l er gy Therapeu tics p lc
(" A l l ergy Ther apeut ics", the "Group" or "C o mpany ")
Exercise of Options and Total Voting Rights
Rule 2.9 announcement
9 November 2023 Allergy Therapeutics plc (AIM: AGY ) announces
that the Company has allotted and issued a total of 5,229,074 new
ordinary shares of GBP0.001 each in the Company ("New Ordinary
Shares") following the exercise of 5,229,074 options by certain
current and former employees. Of these, 5,197,965 options were
exercised as a result of the recent equity financing that
constituted a change of control for the purposes of the Company's
Long Term Share Incentive Plan and 31,109 options were exercised in
connection with proposals made to the holders of those options
pursuant to Rule 15 of the Code, as described in the offer document
published on 19 October 2023.
As a result of the exercise of options, the New Ordinary Shares
have been admitted to trading on AIM pursuant to the Company's
existing block admission facility. The New Ordinary Shares rank
pari passu with the existing shares of the Company.
In accordance with Rule 2.9 of the City Code on Takeovers and
Mergers the Company confirms that, on 9 November 2023 (the date of
this announcement), it has 4,758,946,227 ordinary shares of
GBP0.001 each in issue. This figure may be used by shareholders as
the denominator for the calculations by which they will determine
if they are required to notify their interest in, or a change to
their interest in, the Company under the FCA's Disclosure Guidance
and Transparency Rules.
The International Securities Identification Number for Allergy
Therapeutics Shares is GB00B02LCQ05.
For further information, please contact:
Allergy Therapeutics
Manuel Llobet, Chief Executive Officer
Shaun Furlong, Chief Financial Officer
+44 (0)1903 845 820
Panmure Gordon (Rule 3 Adviser, Nominated Adviser and
Broker)
Emma Earl, Mark Rogers, Freddy Crossley, Corporate Finance
Rupert Dearden, Corporate Broking
+44 (0)20 7886 2500
ICR Consilium
Mary-Jane Elliott / David Daley / Davide Salvi
+44 (0)20 3709 5700
allergytherapeutics@consilium-comms.com
Notes for editors:
About Allergy Therapeutics
Allergy Therapeutics is an international commercial
biotechnology company, headquartered in the UK, focussed on the
treatment and diagnosis of allergic disorders, including aluminium
free immunotherapy vaccines that have the potential to cure
disease. The Group sells proprietary and third-party products from
its subsidiaries in nine major European countries and via
distribution agreements in an additional ten countries. Its broad
pipeline of products in clinical development includes vaccines for
grass, tree, house dust mite and peanut. For more information,
please see www.allergytherapeutics.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
TVRFSLFSUEDSELF
(END) Dow Jones Newswires
November 09, 2023 05:48 ET (10:48 GMT)
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Apr 2023 to Apr 2024